CHRONIC PAIN

Venodol Roll-on — Long-lasting chronic pain relief

Venodol Roll-on — Long-lasting Chronic Pain Relief

Spotlight Innovation subsidiary Caretta Therapeutics is developing and commercializing products, derived from cobra venom, that have potential analgesic properties for the relief of chronic pain associated with inflammation. Caretta Therapeutics has entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize products derived from snake venom that may provide analgesic relief from moderate to severe chronic pain. Under the terms of the agreement, Dr. Reid has agreed to grant an exclusive, worldwide license to Caretta Therapeutics to develop, manufacture and sell the products. The products will be available as over-the-counter formulations.

Caretta Therapeutics’ first commercial product, Venodol Roll-on, is available online at Venodol.com, Walmart.com and Amazon.com.

PRESS RELEASES

JANUARY 11, 2018
Venodol Roll-on, Spotlight Innovation’s New Analgesic Product, Now Available at Amazon.com

SEPTEMBER 27, 2017
Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product “Venodol”

AUGUST 7, 2017
New Chronic Pain Relief Product “Venodol” Now Available for Pre-order at Venodol.com

JULY 11, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Engages Public Relations Firm TransMedia Group

JUNE 14, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Signs Second Venodol API Production Agreement

MAY 31, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Begins the Manufacturing Process for Venodol, a New Over-the-Counter Product to Treat Chronic Pain

JANUARY 18, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Announces Venodol, a New Over-the-counter Product to Treat Chronic Pain

OCTOBER 6, 2016
Spotlight Innovation’s Newly Established Subsidiary Caretta Therapeutics Enters into Exclusive Licensing Agreement to Develop and Commercialize Analgesic Products